Business · 01/05/2026Updated: 10/16/2026 · 1 min read

FDA Identifies Three Bulk Drug Substances Not to be Included on 503B Bulks List

Summary

The FDA has evaluated and proposes not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List, a list of bulk drug substances for which there is a clinical need for outsourcing facilities to use in compounding.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News Central Bank Policy News

Related business signals

Business · 9/17/2026

Proposed Data Collection Activity for Diaper Distribution Demonstration and Research Pilot Beneficiary and Organizational Survey

The Administration for Children and Families, Department of Health and Human Services, is proposing to continue collecting data on diaper need and outcomes for beneficiaries of the Diaper Distribution Demonstration and Research Pilot, with proposed changes to the Beneficiary Survey and addition of an Organizational Survey.

Read summary →

Business · 9/16/2026

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencing

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Microbiology Devices Panel to discuss pathogen-agnostic sequencing for emergency preparedness and response efforts.

Read summary →

Business · 9/16/2026

Food and Drug Administration Announces Proposed Collection of Information for Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Read summary →

Business · 9/16/2026

Medicare Program; Public Meeting for New Revisions to the Healthcare Common Procedure Coding System (HCPCS) Level II Coding

The Centers for Medicare and Medicaid Services (CMS) will hold its second biannual Healthcare Common Procedure Coding System (HCPCS) Level II public meeting of 2026 to discuss new revisions to the HCPCS Level II code set for non-drug and non-biological items and services.

Read summary →

Business · 9/15/2026

FDA Establishes Public Docket for Rare Disease Clinical Investigations Statistical Considerations

The FDA is collecting feedback on statistical considerations for rare disease clinical investigations through a public docket, which is open until a certain date, and a Rare Disease Innovation, Science, and Exploration (RISE) Workshop on the topic.

Read summary →

Business · 9/15/2026

World Trade Center Health Program Denies Stroke Petitions

The World Trade Center Health Program Administrator has denied petitions to add stroke to the list of WTC-related health conditions due to insufficient evidence, and therefore will not request a recommendation from the WTC Health Program Scientific/Technical Advisory Committee or publish a proposed rule.

Read summary →